Actively Recruiting
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Led by Oslo University Hospital · Updated on 2021-07-28
300
Participants Needed
1
Research Sites
934 weeks
Total Duration
On this page
Sponsors
O
Oslo University Hospital
Lead Sponsor
T
The Research Council of Norway
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through animal models to explore different treatment strategies for peritoneal surface malignancies (PSM).
CONDITIONS
Official Title
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Confirmed diagnosis of peritoneal surface malignancy
- Candidate for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
- Written informed consent
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Norwegian Radium Hospital
Oslo, Norway
Actively Recruiting
Research Team
K
Kjersti Flatmark, MD PhD
CONTACT
A
Annette Torgunrud Kristensen, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here